SEER Cancer Statistics Factsheets: Common Cancer Sites. National Cancer Institute. Available from: https://seer.cancer.gov/statfacts/html/common.html. Accessed 15 Aug 2023.

Cancer Facts & Figures 2023. American Cancer Society, Inc. 2022.

Schorge JO, et al. The effect of postsurgical therapy on stage III endometrial carcinoma. Gynecol Oncol. 1996;63(1):34–9.

Article  PubMed  CAS  Google Scholar 

Siegel RL, Miller KD, Wagle NS, Jemal A. Cancer statistics, 2023. CA Cancer J Clin. 2023;73(1):17–48.

Article  PubMed  Google Scholar 

Armstrong DK, et al. Ovarian Cancer, Version 2.2020, NCCN Clinical Practice Guidelines in Oncology. J Natl Compr Canc Netw, 2021;19(2):191-226.

Brooks RA, et al. Current recommendations and recent progress in endometrial cancer. CA Cancer J Clin. 2019;69(4):258–79.

Article  PubMed  Google Scholar 

Marth C, et al. Cervical cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2018;29(Suppl 4):iv262.

Aghajanian C, et al. OCEANS: a randomized, double-blind, placebo-controlled phase III trial of chemotherapy with or without bevacizumab in patients with platinum-sensitive recurrent epithelial ovarian, primary peritoneal, or fallopian tube cancer. J Clin Oncol. 2012;30(17):2039–45.

Article  PubMed  PubMed Central  CAS  Google Scholar 

Burger RA, et al. Incorporation of bevacizumab in the primary treatment of ovarian cancer. N Engl J Med. 2011;365(26):2473–83.

Article  PubMed  CAS  Google Scholar 

Pujade-Lauraine E, et al. Bevacizumab combined with chemotherapy for platinum-resistant recurrent ovarian cancer: the AURELIA open-label randomized phase III trial. J Clin Oncol. 2014;32(13):1302–8.

Article  PubMed  CAS  Google Scholar 

Tewari KS, et al. Improved survival with bevacizumab in advanced cervical cancer. N Engl J Med. 2014;370(8):734–43.

Article  PubMed  PubMed Central  CAS  Google Scholar 

Gonzalez-Martin A, et al. Niraparib in patients with newly diagnosed advanced ovarian cancer. N Engl J Med. 2019;381(25):2391–402.

Article  PubMed  CAS  Google Scholar 

Monk BJ, et al. A randomized, phase III trial to evaluate rucaparib monotherapy as maintenance treatment in patients with newly diagnosed ovarian cancer (ATHENA-MONO/GOG-3020/ENGOT-ov45). J Clin Oncol. 2022;40(34):3952–64.

Article  PubMed  PubMed Central  CAS  Google Scholar 

Moore K, et al. Maintenance olaparib in patients with newly diagnosed advanced ovarian cancer. N Engl J Med. 2018;379(26):2495–505.

Article  PubMed  CAS  Google Scholar 

Le DT, et al. PD-1 blockade in tumors with mismatch-repair deficiency. N Engl J Med. 2015;372(26):2509–20.

Article  PubMed  PubMed Central  CAS  Google Scholar 

Marabelle A, et al. Efficacy of pembrolizumab in patients with noncolorectal high microsatellite instability/mismatch repair-deficient cancer: results from the phase II KEYNOTE-158 study. J Clin Oncol. 2020;38(1):1–10.

Article  PubMed  CAS  Google Scholar 

O’Malley DM, et al. Pembrolizumab in patients with microsatellite instability-high advanced endometrial cancer: results from the KEYNOTE-158 study. J Clin Oncol. 2022;40(7):752–61.

Article  PubMed  PubMed Central  Google Scholar 

Eskander RN, et al. Pembrolizumab plus chemotherapy in advanced endometrial cancer. N Engl J Med. 2023;388(23):2159–70.

Article  PubMed  PubMed Central  CAS  Google Scholar 

Mirza MR, et al. Dostarlimab for primary advanced or recurrent endometrial cancer. N Engl J Med. 2023;388(23):2145–58.

Article  PubMed  CAS  Google Scholar 

Colombo N, et al. Pembrolizumab for persistent, recurrent, or metastatic cervical cancer. N Engl J Med. 2021;385(20):1856–67.

Article  PubMed  CAS  Google Scholar 

Lundqvist EA, Fujiwara K, Seoud M. Principles of chemotherapy. Int J Gynaecol Obstet. 2015;131(Suppl 2):S146-9.

PubMed  Google Scholar 

Tarantino P, et al. Antibody-drug conjugates: smart chemotherapy delivery across tumor histologies. CA Cancer J Clin. 2022;72(2):165–82.

Article  PubMed  Google Scholar 

Calo CA, O’Malley DM. Antibody-drug conjugates for the treatment of ovarian cancer. Expert Opin Biol Ther. 2021;21(7):875–87.

Article  PubMed  CAS  Google Scholar 

Drago JZ, Modi S, Chandarlapaty S. Unlocking the potential of antibody-drug conjugates for cancer therapy. Nat Rev Clin Oncol. 2021;18(6):327–44.

Article  PubMed  PubMed Central  Google Scholar 

Damelin M, Zhong W, Myers J, Sapra P. Evolving strategies for target selection for antibody-drug conjugates. Pharm Res. 2015;32(11):3494–507.

Article  PubMed  CAS  Google Scholar 

Donaghy H. Effects of antibody, drug and linker on the preclinical and clinical toxicities of antibody-drug conjugates. MAbs. 2016;8(4):659–71.

Article  PubMed  PubMed Central  CAS  Google Scholar 

Schlothauer T, et al. Novel human IgG1 and IgG4 Fc-engineered antibodies with completely abolished immune effector functions. Protein Eng Des Sel. 2016;29(10):457–66.

Article  PubMed  CAS  Google Scholar 

Shen BQ, et al. Conjugation site modulates the in vivo stability and therapeutic activity of antibody-drug conjugates. Nat Biotechnol. 2012;30(2):184–9.

Article  PubMed  CAS  Google Scholar 

Zhang D, Goldberg MV, Chiu ML. Fc Engineering approaches to enhance the Agonism and effector functions of an Anti-OX40 antibody. J Biol Chem. 2016;291(53):27134–46.

Article  PubMed  PubMed Central  CAS  Google Scholar 

Gerlinger M, et al. Intratumor heterogeneity and branched evolution revealed by multiregion sequencing. N Engl J Med. 2012;366(10):883–92.

Article  PubMed  PubMed Central  CAS  Google Scholar 

Chen H, Lin Z, Arnst KE, Miller DD, Li W. Tubulin inhibitor-based antibody-drug conjugates for cancer therapy. Molecules. 2017;22(8):1281.

Pahl A, Lutz C, Hechler T. Amanitins and their development as a payload for antibody-drug conjugates. Drug Discov Today Technol. 2018;30:85–9.

Article  PubMed  Google Scholar 

Fu Z, et al. Antibody drug conjugate: the “biological missile” for targeted cancer therapy. Signal Transduct Target Ther. 2022;7(1):93.

Article  PubMed  PubMed Central  CAS  Google Scholar 

Hamblett KJ, et al. Effects of drug loading on the antitumor activity of a monoclonal antibody drug conjugate. Clin Cancer Res. 2004;10(20):7063–70.

Article  PubMed  CAS  Google Scholar 

Jain N, Smith SW, Ghone S, Tomczuk B. Current ADC Linker Chemistry. Pharm Res. 2015;32(11):3526–40.

Article  PubMed  PubMed Central  CAS  Google Scholar 

Sheyi R, de la Torre BG, Albericio F. Linkers: an assurance for controlled delivery of antibody-drug conjugate. Pharmaceutics. 2022;14(2):396.

Kovtun YV, et al. Antibody-drug conjugates designed to eradicate tumors with homogeneous and heterogeneous expression of the target antigen. Cancer Res. 2006;66(6):3214–21.

Article  PubMed  CAS  Google Scholar 

Polson AG, et al. Antibody-drug conjugates for the treatment of non-Hodgkin‘s lymphoma: target and linker-drug selection. Cancer Res. 2009;69(6):2358–64.

Article  PubMed  CAS  Google Scholar 

McCombs JR, Owen SC. Antibody drug conjugates: design and selection of linker, payload and conjugation chemistry. AAPS J. 2015;17(2):339–51.

Article  PubMed  PubMed Central  CAS  Google Scholar 

Masters JC, et al. Clinical toxicity of antibody drug conjugates: a meta-analysis of payloads. Invest New Drugs. 2018;36(1):121–35.

Article  PubMed  CAS  Google Scholar 

Zhu Y, Liu K, Wang K, Zhu H. Treatment-related adverse events of antibody-drug conjugates in clinical trials: a systematic review and meta-analysis. Cancer. 2023;129(2):283–95.

Article  PubMed  CAS  Google Scholar 

Eaton JS, Miller PE, Mannis MJ, Murphy CJ. Ocular adverse events associated with antibody-drug conjugates in human clinical trials. J Ocul Pharmacol Ther. 2015;31(10):589–604.

Article  PubMed  PubMed Central  CAS  Google Scholar